[go: up one dir, main page]

CL2017001843A1 - Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. - Google Patents

Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.

Info

Publication number
CL2017001843A1
CL2017001843A1 CL2017001843A CL2017001843A CL2017001843A1 CL 2017001843 A1 CL2017001843 A1 CL 2017001843A1 CL 2017001843 A CL2017001843 A CL 2017001843A CL 2017001843 A CL2017001843 A CL 2017001843A CL 2017001843 A1 CL2017001843 A1 CL 2017001843A1
Authority
CL
Chile
Prior art keywords
lixisenatide
treatment
pharmaceutically acceptable
acceptable salt
type
Prior art date
Application number
CL2017001843A
Other languages
English (en)
Inventor
Karin Bergmann
Agnes Hincelin-Mery
Christelle Jan
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52354814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001843(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CL2017001843A1 publication Critical patent/CL2017001843A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>LA PRESENTE INVENCIOÓN SE REFIERE A LIXISENATIDA PARA USO EN PACIENTES PEDIÁTRICOS.</p>
CL2017001843A 2015-01-16 2017-07-14 Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. CL2017001843A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15151488 2015-01-16
PCT/EP2016/050804 WO2016113404A1 (en) 2015-01-16 2016-01-15 Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide

Publications (1)

Publication Number Publication Date
CL2017001843A1 true CL2017001843A1 (es) 2018-02-23

Family

ID=52354814

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001843A CL2017001843A1 (es) 2015-01-16 2017-07-14 Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.

Country Status (22)

Country Link
US (4) US20160235818A1 (es)
EP (1) EP3244912B1 (es)
JP (1) JP7274258B2 (es)
KR (1) KR102614574B1 (es)
CN (1) CN107405386A (es)
AR (1) AR103415A1 (es)
AU (1) AU2016207964B2 (es)
CA (1) CA2973632A1 (es)
CL (1) CL2017001843A1 (es)
CR (1) CR20170376A (es)
EA (1) EA035423B1 (es)
ES (1) ES2895513T3 (es)
IL (1) IL253460B (es)
MX (1) MX381944B (es)
PH (1) PH12017501290A1 (es)
PL (1) PL3244912T3 (es)
PT (1) PT3244912T (es)
SG (1) SG11201705755UA (es)
TN (1) TN2017000292A1 (es)
TW (1) TWI706779B (es)
WO (1) WO2016113404A1 (es)
ZA (1) ZA201704512B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
DE102019129444A1 (de) * 2019-10-31 2021-05-06 Lts Lohmann Therapie-Systeme Ag Lagtime-Verkürzung/Eisspray
WO2022221177A1 (en) * 2021-04-11 2022-10-20 Khurana Vikas Diagnosis and treatment of congestive colon failure (ccf)
WO2024133412A1 (en) 2022-12-21 2024-06-27 Novo Nordisk A/S Methods and systems for estimating fbg value from cgm data

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
WO2010138671A1 (en) * 2009-05-28 2010-12-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
PL2324853T3 (pl) * 2009-11-13 2016-01-29 Sanofi Aventis Deutschland Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
BR112013029062A2 (pt) 2011-05-13 2016-11-29 Sanofi Aventis Deutschland lixisenatida e metformina para o tratamento de diabetes tipo 2
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
BR112014004726A2 (pt) * 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
JP6329487B2 (ja) * 2011-10-28 2018-05-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療プロトコル

Also Published As

Publication number Publication date
EA035423B1 (ru) 2020-06-11
US20190365864A1 (en) 2019-12-05
CN107405386A (zh) 2017-11-28
AU2016207964A1 (en) 2017-08-31
KR20170102550A (ko) 2017-09-11
CA2973632A1 (en) 2016-07-21
US20160235818A1 (en) 2016-08-18
MX381944B (es) 2025-03-13
MX2017009294A (es) 2017-11-20
PL3244912T3 (pl) 2021-12-20
AU2016207964B2 (en) 2021-10-14
ES2895513T3 (es) 2022-02-21
US20210187075A1 (en) 2021-06-24
CR20170376A (es) 2017-09-25
WO2016113404A1 (en) 2016-07-21
SG11201705755UA (en) 2017-08-30
TWI706779B (zh) 2020-10-11
EA201791611A1 (ru) 2017-11-30
BR112017015099A2 (pt) 2018-04-17
EP3244912A1 (en) 2017-11-22
NZ734595A (en) 2022-03-25
IL253460A0 (en) 2017-09-28
JP7274258B2 (ja) 2023-05-16
PH12017501290A1 (en) 2018-02-05
AR103415A1 (es) 2017-05-10
PT3244912T (pt) 2021-10-27
EP3244912B1 (en) 2021-08-18
TW201639551A (zh) 2016-11-16
US20240173384A1 (en) 2024-05-30
ZA201704512B (en) 2019-07-31
JP2018503644A (ja) 2018-02-08
TN2017000292A1 (en) 2019-01-16
IL253460B (en) 2022-06-01
KR102614574B1 (ko) 2023-12-18

Similar Documents

Publication Publication Date Title
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
MX2017012926A (es) Inhibidores y sus usos.
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
CL2017003143A1 (es) Composición multi-péptido.
MX2015017136A (es) Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.
AR103944A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
AR102978A1 (es) Formulación de relación fija de insulina glargina / lixisenatida
PL3897537T3 (pl) Kompozycja do pielęgnacji osobistej o zwiększonym uwalnianiu oparów
HK1239556A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis
CL2011001916A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico.
AR099638A1 (es) El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmacéuticamente aceptable del mismo en la prevención y el tratamiento de la diabetes